Sign Up Today and Learn More About Evergreen Theragnostics Stock
Invest in or calculate the value of your shares in Evergreen Theragnostics or other pre-IPO companies through EquityZen's platform.
Evergreen Theragnostics Stock (EVTH)
Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development&Manufacturing Organization
About Evergreen Theragnostics Stock
Founded
2019
Headquarters
Jersey City, NJ, US
Industries
Software, Artificial Intelligence, Data and Analytics
Evergreen Theragnostics Press Mentions
Stay in the know about the latest news on Evergreen Theragnostics
Orbit Discovery and Evergreen Theragnostics Expand Research Collaboration to Advance Targeted Therapeutics Development
morningstar • Dec 03, 2024
Orbit Discovery and Evergreen Theragnostics Expand Research Collaboration to Advance Targeted Therapeutics Development
businesswire • Dec 03, 2024
Evergreen Theragnostics, Inc. on Wednesday broke ground on its new manufacturing facility in Springfield.
njbiz • Aug 04, 2024
Dr. Morgan on the evolving field of salvage therapy in prostate cancer
linkedin • Aug 04, 2024
Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer
prnewswire • Aug 04, 2024
Evergreen Theragnostics Management
Leadership team at Evergreen Theragnostics
Chief Executive Officer & Founder
James Cook
SENIOR ADVISOR & CO-FOUNDER
Serge Lyashchenko
Join now and verify your accreditation status to gain access to:
- Evergreen Theragnostics current valuation
- Evergreen Theragnostics stock price
- Available deals in Evergreen Theragnostics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Evergreen Theragnostics Stock
How to invest in Evergreen Theragnostics stock?
Accredited investors can buy pre-IPO stock in companies like Evergreen Theragnostics through EquityZen funds. These investments are made available by existing Evergreen Theragnostics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Evergreen Theragnostics stock?
Shareholders can sell their Evergreen Theragnostics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
